TREM2
TREM2 (triggering receptor expressed on myeloid cells 2, also TREM-2) is a membrane receptor that partners with TYROBP to drive cell activation after ligand binding. It is best known for its roles in microglial phagocytosis, lipid sensing and the regulation of inflammatory signalling. Browse Assay Genie's current range of TREM2 research reagents below, or read on for the biology behind the target.
TREM2 forms a receptor signalling complex with TYROBP, which mediates signalling and cell activation after ligand binding. It acts as a receptor for amyloid-beta 42, a cleavage product of APP, and mediates its uptake and degradation by microglia. It also binds lipoprotein particles such as LDL, VLDL and HDL, apolipoproteins including APOE and CLU, and anionic phospholipids such as phosphatidylserine, enhancing lipid uptake in microglia.
In microglia, TREM2 is required for phagocytosis of apoptotic neurons, myelin debris after neuronal injury, and synapses during elimination in the developing brain. It regulates microglial proliferation as an upstream regulator of Wnt/beta-catenin signalling, and influences chemotaxis, process outgrowth, mTOR activation, metabolism and age-related changes in microglial numbers. In response to lipopolysaccharide it suppresses PI3K and NF-kappa-B signalling, promoting phagocytosis, limiting pro-inflammatory cytokine and nitric oxide production, and increasing IL10 and TGFB expression. During oxidative stress it promotes anti-apoptotic NF-kappa-B and ERK signalling.
Beyond microglia, TREM2 triggers immune responses in macrophages and dendritic cells, mediates cytokine-induced formation of multinucleated giant cells, and supports osteoclast differentiation. In dendritic cells it is a receptor for SEMA6D, with PLEXNA1 as coreceptor, and promotes CCR7 up-regulation, maturation and survival. The TREM2 gene belongs to the V-set domain containing group; alternative splicing yields multiple isoforms, and defects in the gene cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL). The human gene was previously named triggering receptor expressed on myeloid cells 2a, and the mouse ortholog is Trem2.
TREM2 governs microglial activation, proliferation, chemotaxis and the balance between pro- and anti-inflammatory cytokine output.
TREM2 is a receptor for amyloid-beta 42 and mediates its uptake and degradation by microglia.
TREM2 binds lipoproteins, apolipoproteins and anionic phospholipids, and contributes to microglial metabolism through mTOR activation.
TREM2 supports osteoclast differentiation, macrophage giant cell formation and dendritic cell maturation and survival.
TREM2 pairs with TYROBP to transmit activation signals after ligand binding. In microglia it mediates uptake of amyloid-beta 42, lipoproteins and phospholipids, and drives phagocytosis of apoptotic neurons, myelin debris and synapses. It also regulates inflammatory signalling through PI3K and NF-kappa-B.
TREM2 is also written TREM-2, with the aliases Trem2a, Trem2b and Trem2c, and the previous name triggering receptor expressed on myeloid cells 2a. UniProt lists the protein as both cell membrane and secreted, and alternative splicing produces multiple transcript variants encoding different isoforms.
Defects in the TREM2 gene cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL). The gene has a mouse ortholog, Trem2, so findings can be compared across species; check the datasheet of any product for its validated reactivity.
Other TREM family and TREM-like receptors involved in myeloid cell signalling and immune regulation.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q9NZC2; product specifications from Assay Genie datasheets.